Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.46 |
| ▸ | PYGL | P06737 | 2/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 12/20 | 0.44 |
| ▸ | MC3R | P41968 | 12/20 | 0.44 |
| ▸ | MC1R | Q01726 | 12/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401593 | 0.94 | F2 (0.50) | F2CYP51A1PYGLTACR1OPRD1 | |
| SCHEMBL1401268 | 0.86 | OPRD1 (0.48) | F2CYP51A1TACR1OPRD1 | |
| SCHEMBL1401188 | 0.86 | OPRD1 (0.44) | F2TACR1MC4ROPRD1 | |
| SCHEMBL3361699 | 0.84 | CYP51A1 (0.46) | F2CYP51A1PYGLOPRD1 | |
| SCHEMBL1401284 | 0.83 | HSD17B10 (0.47) | F2 | |
| SCHEMBL6318813 | 0.81 | MMP9 (0.47) | F2TACR1MC4RMC3RMC1R | |
| SCHEMBL14048408 | 0.80 | OPRD1 (0.40) | F2CYP51A1PYGLPYGMTACR1 | |
| SCHEMBL1401107 | 0.80 | TACR1 (0.42) | F2TACR1 | |
| SCHEMBL1401110 | 0.80 | TACR1 (0.42) | F2TACR1 | |
| SCHEMBL867815 | 0.80 | GHSR (0.54) | F2MC4RMC3RMC1ROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100824-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2011-03-02 | — | — | EP | claimed |
| EP-1789067-B8 | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system | HELSINN HEALTHCARE SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2134341-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008100448-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1789067-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006020930-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |